Abstract

Aim: To assess the effects of hormone therapy (HRT), drospirenone (DRSP) plus 17 β-estradiol (E2) on the climacteric symptoms control in patients treated at the gynecology consultation in the Hospital “Dr. Manuel Noriega Trigo”. Patients and Methods: We performed comparative and applied research with quasi-experimental, case-control, single-masked, prospective, longitudinal, and field design, with a systematic random sample of 120 women separated to receive either the combination DRSP/E2 (Group A) or placebo (Group B). Clinical interviews assessed the climacteric symptoms before and after six months of receiving this HRT. Result: After treatment, DRSP/ E2, when compared to placebo, was found to have a significant reduction in vasomotor symptoms, psychological symptoms, and urinary incontinence (p<0.001). In group B, only vasomotor and psychological symptoms were significantly reduced (p<0.001). Conclusion: DRSP/1E2, at a dose of 2/1 mg respectively, proved effective after six months of treatment to control climacteric symptoms, with few and mild side effects.